Medicare Enrolled
Dr. Thomas Gregory, M.D.
Medical Oncology · Tyler, TX
Practice pattern: Mixed Practice— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Gregory from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Gregory? Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Gregory
Dr. Thomas Gregory is a medical oncology in Tyler, TX, with 19 years in practice. Based on federal Medicare data, Dr. Gregory performed 140,067 Medicare services across 4,911 unique beneficiaries.
Between the years covered by Open Payments, Dr. Gregory received a total of $2,757 from 45 pharmaceutical and/or device companies across 131 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in medical oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Gregory is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 19 years in practice▲ Top 4% volume in TX$ $2,757 industry payments
Medicare Practice Summary
Medicare Utilization ↗140,067
Medicare services
Top 4% in TX for medical oncology
4,911
Unique beneficiaries
$17
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~7,372 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron infusion (Feraheme) | 20,910 | $0 | $5 |
| Pembrolizumab injection (Keytruda) | 17,200 | $43 | $137 |
| Nivolumab injection (Opdivo) | 14,460 | $24 | $76 |
| Oxaliplatin chemotherapy injection | 11,600 | $0 | $33 |
| Paclitaxel chemotherapy injection | 9,100 | $0 | $8 |
| Iron sucrose injection (Venofer) | 9,000 | $0 | $2 |
| Daratumumab injection (Darzalex) | 9,000 | $38 | $126 |
| Darbepoetin injection (Aranesp) for anemia | 8,209 | $2 | $20 |
| Contrast dye for imaging (iodine-based) | 7,320 | $0 | $3 |
| Injection, docetaxel, 1 mg | 3,562 | $0 | $66 |
| Dexamethasone injection (steroid) | 3,073 | $0 | $1 |
| Injection, durvalumab, 10 mg | 2,880 | $62 | $197 |
| Immune globulin infusion (Octagam) | 2,864 | $34 | $234 |
| Anti-nausea injection (fosaprepitant) | 1,800 | $0 | $5 |
| Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg | 1,771 | $25 | $155 |
| Injection, ipilimumab, 1 mg | 1,650 | $131 | $417 |
| Denosumab injection (Prolia/Xgeva) | 1,500 | $18 | $66 |
| Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg | 1,200 | $23 | $181 |
| Injection, granisetron hydrochloride, 100 mcg | 1,120 | $0 | $24 |
| Blood draw (venipuncture) | 1,113 | $8 | $20 |
| Complete blood count (CBC) with differential | 1,011 | $8 | $36 |
| Comprehensive metabolic blood panel | 940 | $10 | $64 |
| Office visit, established patient (30-39 min) | 694 | $88 | $368 |
| Injection of additional new drug or substance into vein | 633 | $11 | $108 |
| Administration of chemotherapy into vein, 1 hour or less | 491 | $97 | $707 |
| Injection, leucovorin calcium, per 50 mg | 485 | $3 | $25 |
| Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | 456 | $88 | $1,348 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 400 | $3 | $373 |
| Anti-nausea injection (Aloxi/palonosetron) | 370 | $1 | $114 |
| Injection, fluorouracil, 500 mg | 362 | $2 | $13 |
| Injection, carboplatin, 50 mg | 345 | $2 | $300 |
| Injection, zoledronic acid, 1 mg | 310 | $7 | $431 |
| Cyclophosphamide, 100 mg | 270 | $16 | $203 |
| Intensity modulated treatment delivery, single or multiple fields/arcs,via narrow spatially and temporally modulated beams, binary, dynamic mlc, per treatment session | 207 | $272 | $2,762 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 200 | $46 | $313 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 196 | $21 | $157 |
| Injection, potassium chloride, per 2 meq | 195 | $0 | $1 |
| Ferritin level test (iron stores) | 161 | $13 | $60 |
| Lactate dehydrogenase (enzyme) level | 156 | $6 | $31 |
| Administration of additional new drug or substance into vein, 1 hour or less | 152 | $48 | $344 |
| Injection, diphenhydramine hcl, up to 50 mg | 149 | $1 | $7 |
| Iron level test | 142 | $6 | $27 |
| Iron binding capacity test | 142 | $9 | $35 |
| Office visit, established patient (20-29 min) | 141 | $63 | $250 |
| Drug injection, under skin or into muscle | 135 | $10 | $96 |
| Injection, cisplatin, powder or solution, 10 mg | 133 | $2 | $94 |
| Injection, magnesium sulfate, per 500 mg | 126 | $1 | $6 |
| Administration of chemotherapy into vein, each additional hour | 115 | $21 | $161 |
| Reticulated (young) platelet measurement | 113 | $34 | $143 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 111 | $53 | $211 |
| Microscopic examination for white blood cells with manual cell count | 109 | $4 | $22 |
| Complete blood count (CBC), automated | 109 | $6 | $34 |
| Injection, fosnetupitant 235 mg and palonosetron 0.25 mg | 96 | $336 | $1,722 |
| Carcinoembryonic antigen (cea) protein level | 89 | $19 | $99 |
| Ct scan of chest with contrast | 70 | $47 | $821 |
| Magnesium level test | 62 | $7 | $29 |
| Unclassified drugs | 62 | $1 | $8 |
| New patient office visit (45-59 min) | 57 | $120 | $565 |
| Infusion, normal saline solution , 1000 cc | 55 | $2 | $19 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 53 | $16 | $100 |
| Radiation treatment delivery,3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 11-19 mev | 53 | $178 | $700 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 48 | $24 | $145 |
| CT scan of abdomen and pelvis with contrast | 47 | $161 | $1,067 |
| Red blood count, automated test | 45 | $4 | $23 |
| Irrigation of implanted venous access drug delivery device | 44 | $17 | $114 |
| PSA test (prostate cancer screening) | 41 | $18 | $94 |
| Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | 41 | $121 | $500 |
| Application of on-body injector for under skin injection | 37 | $14 | $96 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 32 | $15 | $94 |
| Hospital follow-up visit, moderate complexity | 32 | $59 | $247 |
| Vitamin B-12 level test | 31 | $15 | $76 |
| CT scan of chest, without contrast | 29 | $53 | $686 |
| Administration of additional new drug or substance into vein using push technique | 28 | $42 | $289 |
| Infusion into a vein for hydration, 31-60 minutes | 27 | $25 | $256 |
| Infusion into a vein for hydration, each additional hour | 24 | $10 | $75 |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 21 | $1 | $19 |
| Drawing of blood for a medical problem | 16 | $46 | $264 |
| Ct scan of abdomen and pelvis before and after contrast | 13 | $170 | $1,413 |
| Urea nitrogen level to assess kidney function, quantitative | 12 | $4 | $24 |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 11 | $1,109 | $4,802 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
17.4% high complexity
78.3% medium
4.3% routine
Industry Payment Transparency
Open Payments through 2024 ↗$2,757
Total received (2018-2024)
Avg $394/year across 7 years
Bottom 44% in TX for medical oncology
45
Companies
131
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$2,658 (96.4%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$99 (3.6%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024$1,194
2023$564
2022$478
2021$221
2020$134
2019$44
2018$122
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
AstraZeneca Pharmaceuticals LP
$230
E.R. Squibb & Sons, L.L.C.
$167
Regeneron Healthcare Solutions, Inc.
$160
Tempus AI, Inc
$157
ABBVIE INC.
$155
GlaxoSmithKline, LLC.
$138
GENZYME CORPORATION
$135
Takeda Pharmaceuticals U.S.A., Inc.
$117
Janssen Scientific Affairs, LLC
$108
SOBI, INC
$92
Seagen Inc.
$87
Incyte Corporation
$87
Lilly USA, LLC
$81
Daiichi Sankyo Inc.
$80
Novartis Pharmaceuticals Corporation
$78
Ipsen Biopharmaceuticals, Inc
$69
Janssen Biotech, Inc.
$69
Pharmacyclics LLC, An AbbVie Company
$64
JAZZ PHARMACEUTICALS INC.
$64
Alexion Pharmaceuticals, Inc.
$60
PFIZER INC.
$49
Kite Pharma, Inc.
$39
Myriad Genetic Laboratories, Inc.
$39
Immunocore Limited
$29
PUMA BIOTECHNOLOGY, INC.
$28
Aveo Pharmaceuticals, Inc.
$28
Rigel Pharmaceuticals, Inc.
$26
MorphoSys, US Inc.
$25
Pharmacosmos Therapeutics Inc.
$24
G1 Therapeutics, Inc.
$24
Epizyme, Inc.,
$22
Merck Sharp & Dohme LLC
$21
Mirati Therapeutics, Inc.
$20
Genmab U.S., Inc.
$19
Boehringer Ingelheim Pharmaceuticals, Inc.
$19
Stemline Therapeutics Inc.
$19
Astellas Pharma US Inc
$18
Blueprint Medicines Corporation
$17
AbbVie Inc.
$16
Bayer HealthCare Pharmaceuticals Inc.
$16
Emmaus Medical, Inc.
$14
Genentech USA, Inc.
$13
Taiho Oncology, Inc.
$12
Fortovia Therapeutics, Inc.
$12
Gilead Sciences, Inc.
$12
Top 3 companies account for 20.2% of total payments
Associated products mentioned in payments ›
AYVAKIT · COSELA · DARZALEX · DOPTELET · Doptelet · ELITEK · ENHERTU · EPKINLY · Endari · Enhertu · Epkinly · FOTIVDA · GAZYVA · IBRANCE · IMBRUVICA · IMFINZI · IMJUDO · KEYTRUDA · KIMMTRAK · KISQALI · KRAZATI · LIBTAYO · LONSURF · LUTATHERA · MONJUVI · MYRISK · NERLYNX · NINLARO · OJJAARA · OPDIVO · Orserdu · PLUVICTO · Padcev · SARCLISA · SOMATULINE DEPOT · SPRYCEL · TABRECTA · TAGRISSO · TAZVERIK · TECVAYLI · Tavalisse · ULTOMIRIS · VENCLEXTA · VERZENIO · VONJO · VYXEOS · XALKORI · XT CDX · Xofigo · ZEJULA · ZEPZELCA
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (96%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Equivalent to $2 per 100 Medicare services performed
Geographic Context
Medical Oncologys within 10 mi
4
Per 100K population
1.7
County median income
$71,923
Nearest hospital
UT HEALTH EAST TEXAS TYLER REGIONAL HOSPITAL
3.0 mi
3.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Gregory is a mixed practice specialist, with above-average Medicare volume (top 4% in TX), and low-engagement industry engagement, with 19 years of practice experience.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Gregory experienced with iron infusion (feraheme)?
Based on Medicare claims data, Dr. Gregory performed 20,910 iron infusion (feraheme) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Gregory receive payments from pharmaceutical companies?
Yes. Dr. Gregory received a total of $2,757 from 45 companies across 131 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Gregory's costs compare to other medical oncologys in Tyler?
Dr. Gregory's average Medicare payment per service is $17. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Gregory) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Medical Oncologys in Tyler
Browse medical oncologys in Tyler ranked by procedure volume and transparency data.
Highest volume
Top Medical Oncologys in TX
Medical Oncologys ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Medical Oncologys in TX
Which TX medical oncologys receive the most from drug and device companies.
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
By company
E.R. Squibb & Sons, L.L.C. Payments to Doctors
See all physicians who received payments from E.R. Squibb & Sons, L.L.C..
By company
Regeneron Healthcare Solutions, Inc. Payments to Doctors
See all physicians who received payments from Regeneron Healthcare Solutions, Inc..
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology